Denosumab's Impact on Disease-Free Survival New findings point to the potential expanded benefit of denosumab therapy in the management of the breast cancer patient. Denosumab, a human monoclonal antibody that targets RANK ligand and mediates signaling in osteoclastogenesis and bone resorption, is already standard care for preventing skeletal-related complications in patients with solid tumors and bone metastasis. Read more.
Cardiometabolic Effects of Endocrine Therapy for HR+ Breast Cancer Women with breast cancer face a higher risk of death from cardiovascular disease (CVD), and there is interest in determining how antiestrogenic therapy affects this risk. While menopausal hormonal therapy is not recommended for the prevention of CVD, evidence points to a beneficial role of endogenous estrogens in younger or early postmenopausal women. Read more.
Association of Race and Age on Adjuvant Endocrine Adherence Adherence to adjuvant endocrine therapy among women with hormone receptor-positive (HR+) breast cancer (BC) is critical to help decrease morbidity and mortality. Yet, as many as 50% of eligible women either don’t start therapy with an antiestrogenic agent or do not complete their recommended 5-year course of therapy. Read more.
